Phaon conceptualizes and executes studies based on the following three-step model:
The first step involves the development of a concept including the general feasibility analysis, including the statistical and operational feasibility. Once such concept feasibility is finalized, it will be set up with cooperation partners, which includes budget and timelines for set out scope. Such is done through a thorough proposal involving scenario analysis for the trial resulting in realistic budget estimations.
As soon as the financing of the study is settled, the palleos operational team will start with the study set up and full execution of the study. In the end, Phaon will work on the final publication and guarantee scientific dissemination of results.
The Institute of Pathology at the University of Erlangen is an established and high-throughput provider of (breast cancer) pathology and diagnosis
The Institute of Pathology at the University of Erlangen is the exclusive pathology provider of the University of Erlangen and in addition is responsible for more than 30 external referring institutes. The methodological spectrum includes standardized microscopy and immunohistochemistry as well as innovative molecular methods. A highly specialized diagnostic unit / team is particularly focused on breast cancer histopathology and and diagnostics.
Established breast cancer histopathology and molecular diagnostics
The Translational Research Laboratory at the Clinics of Gynecology at the University of Essen hat as a long-standing and profound experience in minimal residual disease (MRD) diagnostics
The Research Group has focused for more than 10 years on the analysis of liquid biopsy and circulating tumor cells and their association with patient prognosis and response to (targeted) therapy. The group has an impressive track record of peer-reviewed publications and presentations at prestigious (inter)national meetings.
OakLabs is a biotech & pharma innovator in the field of precision medicine.
Oaklabs utilizes artificial intelligence algorithms to substantially increase drug efficacy in targeted patient populations.
With modern analytic and biomathematics technology Oaklabs has contributed to projects in the pharmaceutical and medical sector. They have a particular focus on compounds in oncology and autoimmune disease. Their team of quantum physicists and life scientists has a track record in developing superior biomarkers.
modern analytic and biomathematics technology
Provider of artificial intelligence-based network analysis
particular focus on compounds in oncology and autoimmune disease